Copyright
©The Author(s) 2019.
World J Cardiol. Oct 26, 2019; 11(10): 221-235
Published online Oct 26, 2019. doi: 10.4330/wjc.v11.i10.221
Published online Oct 26, 2019. doi: 10.4330/wjc.v11.i10.221
Method | Advantages | Disadvantages |
Retroviral transduction | Efficient, validated for multiple cell types, easy | Transgene integration |
Lentiviral delivery | Very efficient | Transgene integration |
Adenoviral transduction | Does not integrate | Low efficiency, only validated for fibroblasts |
Plasmid DNA transfer (episomal) | Good efficiency, does not integrate, able to replicate autonomously, validated for multiple cell types | Low efficiency in fibroblast reprogramming |
Lox p lentivirus delivery | High efficiency, excision of the integrated sequence, gene expression profile closer to hES cells | Genomic instability and genome rearrangements and loxP site remains integrated |
Sendai virus | Efficient, does not integrate, validated for multiple cell types | Cost if purchased commercially or challenging if generated by a laboratory |
PiggyBAC transposon | Efficient, precise and efficient self-excision, does not remain integrated | Published work only in fibroblasts, licensing patent issues, pBt gene may remain active post-transposition |
Polyarginine tagged polypeptide | Does not integrate | Low efficiency, time-consuming, technically challenging and work only on fibroblasts |
RNA modified synthetic mRNA | Very efficient, does not integrate, factor available commercially | Cost if purchased commercially or challenging if generated by a laboratory and work only on fibroblasts |
- Citation: Jimenez-Tellez N, Greenway SC. Cellular models for human cardiomyopathy: What is the best option? World J Cardiol 2019; 11(10): 221-235
- URL: https://www.wjgnet.com/1949-8462/full/v11/i10/221.htm
- DOI: https://dx.doi.org/10.4330/wjc.v11.i10.221